Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 27 publications
Streamlining the Frequency, Conduct, and Location of Assessments in Registrational Lung Cancer Clinical Trials for Supplemental Applications: Recommendations of a LUNGevity Foundation Multistakeholder Working Group.
Journal: Clinical lung cancer
Published: March 17, 2026
Corrigendum to "Associations of Tissue Tumor Mutational Burden and Mutational Status With Clinical Outcomes With Pembrolizumab Plus Chemotherapy Versus Chemotherapy For Metastatic NSCLC [JTO Clinical and Research Reports Vol. 4 No. 1: 100431].
Journal: JTO clinical and research reports
Published: October 15, 2025
A Time and Motion Study Comparing Subcutaneous Pembrolizumab Versus Intravenous Pembrolizumab in Combination with Chemotherapy for the Treatment of Metastatic Non-small Cell Lung Cancer.
Journal: Advances in therapy
Published: July 16, 2025
Phase III KEYNOTE-789 Study of Pemetrexed and Platinum With or Without Pembrolizumab for Tyrosine Kinase Inhibitor‒Resistant, EGFR-Mutant, Metastatic Nonsquamous Non-Small Cell Lung Cancer.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: August 22, 2024
Patient-Reported Health-Related Quality of Life in KEYNOTE-604: Pembrolizumab or Placebo Added to Etoposide and Platinum as First-Line Therapy for Extensive-Stage SCLC.
Journal: JTO clinical and research reports
Published: June 01, 2023
Real-World Treatment Patterns and Outcomes of First-Line Immunotherapy Among Patients With Advanced Nonsquamous NSCLC Harboring BRAF, MET, or HER2 Alterations.
Journal: JTO clinical and research reports
Published: May 30, 2023
Molecular epidemiology study of programmed death ligand 1 and ligand 2 protein expression assessed by immunohistochemistry in extensive-stage small-cell lung cancer.
Journal: Frontiers in oncology
Published: May 19, 2023
Society for Immunotherapy of Cancer (SITC) consensus definitions for immune checkpoint inhibitor-associated immune-related adverse events (irAEs) terminology.
Journal: Journal for immunotherapy of cancer
Published: February 27, 2023
Pembrolizumab Plus Pemetrexed and Platinum in Nonsquamous Non-Small-Cell Lung Cancer: 5-Year Outcomes From the Phase 3 KEYNOTE-189 Study.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: February 22, 2023
Pembrolizumab Plus Chemotherapy in Squamous Non-Small-Cell Lung Cancer: 5-Year Update of the Phase III KEYNOTE-407 Study.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: February 03, 2023
Associations of Tissue Tumor Mutational Burden and Mutational Status With Clinical Outcomes With Pembrolizumab Plus Chemotherapy Versus Chemotherapy For Metastatic NSCLC.
Journal: JTO clinical and research reports
Published: October 27, 2022
Last Updated: 09/26/2026